Free Trial

Peak Bio Q1 2023 Earnings Report

Peak Bio EPS Results

Actual EPS
-$0.19
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Peak Bio Revenue Results

Actual Revenue
$0.01 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Peak Bio Announcement Details

Quarter
Q1 2023
Time
N/A

Conference Call Resources

Peak Bio Earnings Headlines

$2 Trillion Disappears Because of Fed's Secretive New Move
$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth.
Peak Bio Inc (PKBO)
Peak Bio, Inc. (PKBO)
See More Peak Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Peak Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Peak Bio and other key companies, straight to your email.

About Peak Bio

Peak Bio (NASDAQ:PKBO), a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of patients with inflammatory, cancer, and rare and specialty diseases. The company's lead product candidate is PHP-303, which is in phase 2 clinical study for the treatment of alpha-1 antitrypsin deficiency and acute respiratory distress syndrome. It also develops Trop2 PH1, an antibody-drug-conjugate for solid tumors. The company was founded in 2020 and is based in Pleasanton, California.

View Peak Bio Profile

More Earnings Resources from MarketBeat